Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 2
2(50.0%)
4Total
N/A(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06672822Phase 2Recruiting

Intralesional Injection of STS in Treatment of Calcinosis

Role: lead

NCT06675344Not ApplicableRecruiting

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

Role: lead

NCT04854850Not ApplicableCompleted

Apollo Device for Fatigue in Systemic Sclerosis

Role: lead

NCT02370784Phase 2Completed

Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma

Role: lead

All 4 trials loaded